Results 161 to 170 of about 114,449 (265)

Neurophysin-I dynamics upon different pituitary provocation tests in healthy participants. [PDF]

Endocr Connect
Nikaj A, Atila C, Rudin D, Luethi D, Sailer CO, Winzeler B, Urwyler SA, Refardt J, Liechti ME, Christ-Crain M.   +9 more
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Agents and Body Composition: Filling More Gaps

Obesity, EarlyView.
ABSTRACT The last 2 decades have seen historic advances in the treatment of obesity. We are entering an era of defining obesity not by weight‐based outcomes but by changes in body composition. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are forming the platform for obesity treatments based on their high level of efficacy. Body composition can
Robert L. Dubin, Tierra N. Sanders, Hunter M. Schwab, Steven B. Heymsfield, Frank L. Greenway   +4 more
wiley   +1 more source

Heat shock protein 72 (HSP72) modulates glucagon secretion via JNK inhibition in pancreatic α-cells. [PDF]

Diabetol Int
Watanabe T, Kondo T, Yoshizumi R, Miyakawa N, Kitano S, Suico MA, Sato M, Sakaguchi M, Igata M, Matsumura T, Kai H, Araki E, Kubota N.   +12 more
europepmc   +1 more source

Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults

Obesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate the association of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) with risks of osteoporosis, major osteoporotic fractures, and degenerative musculoskeletal disorders in nondiabetic adults with obesity compared with other obesity medications.
Jie‐Syuan Wu, Lee‐Yuan Lin, Jia‐Wei Sun, Wei‐Ting Yu, Fara Silvia Yuliani, Shyh‐Hsiang Lin   +5 more
wiley   +1 more source

SURMOUNT‐REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity

Obesity, EarlyView.
ABSTRACT Objective SURMOUNT‐REAL UK will evaluate the effectiveness of tirzepatide when offered in addition to standard‐of‐care (SoC) in adults with Class I obesity (BMI ≥ 30 and ≤ 34.9 kg/m2) and without diabetes in a UK primary care setting. Methods A 5‐year, phase 4, multicenter, open‐label, pragmatic randomized clinical trial is enabled through ...
Martin K. Rutter, Julie Mount, J. Martin Gibson, Joanne Webb, Cheryl Marler, Catherine Reed, Mugdha Gore, Wenyu Ye, Elisa Gomez Valderas, John Wilding, Naveed Sattar, Melanie J. Davies, Kamlesh Khunti, Richard Haynes, Rachel L. Batterham   +14 more
wiley   +1 more source

Wernicke's Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case‐Based Evidence

Obesity, EarlyView.
ABSTRACT Objective Glucagon‐like peptide‐1 receptor agonists are increasingly prescribed for obesity. Although generally considered safe, marked appetite suppression and persistent gastrointestinal adverse effects may increase the risk of nutritional deficiencies.
Janice Bidesie, Erik Oudman
wiley   +1 more source

Glucose-dependent dynamics of glucagon, cortisol and adrenocorticotropic hormone before and after gastric bypass. [PDF]

J Endocr Soc
Chronopoulos V, Kjellsson MC, Lundqvist MH.   +2 more
europepmc   +1 more source

Trends of Obesity in Early Adulthood and Later Adulthood Across 196 Countries and Territories, 1990–2022

Obesity, EarlyView.
ABSTRACT Objective We aimed to understand the global burden of obesity in early adulthood and later adulthood over the past three decades. Methods We analyzed obesity prevalence across 196 countries/territories from 1990 to 2022 for early adulthood (age 20–49 years) and later adulthood (age ≥ 50 years) using the Non‐Communicable Disease Risk Factor ...
Abdiwahab M. Ali, Edward Giovannucci, Jason J. Liu   +2 more
wiley   +1 more source

Heterogeneous endocrine cell composition defines human islet functional phenotypes. [PDF]

Nat Commun
Evans-Molina C, Pettway YD, Saunders DC, Sharp SA, Bate TS, Sun H, Durai H, Mei S, Coldren A, Davis C, Reihsmann CV, Hopkirk AL, Taylor J, Bradley A, Aramandla R, Poffenberger G, Eskaros A, Jenkins R, Shi D, Xu K, Kang H, Rajesh V, Thaman S, Feng F, Cartailler JP, Powers AC, Abraham K, IIDP Consortium, Gloyn AL, Niland JC, Brissova M.   +30 more
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists for Obstructive Sleep Apnea With and Without Continuous Positive Airway Pressure

Otolaryngology–Head and Neck Surgery, EarlyView.
Abstract Objective To evaluate glucagon‐like peptide 1 receptor agonists for obstructive sleep apnea compared with controls. Data Sources CINAHL, Cochrane Library, PubMed, and Scopus. Review Methods A PRISMA‐compliant search was conducted from database inception through October 2025.
Cali Loblundo, Sammy Y. Gao, Shaun A. Nguyen, Mohamed Abdelwahab   +3 more
wiley   +1 more source